SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Average Rating of “Moderate Buy” by Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.3333.

Several research firms have issued reports on SABS. Leerink Partnrs raised shares of SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday. Finally, Leerink Partners started coverage on SAB Biotherapeutics in a research note on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price objective on the stock.

SAB Biotherapeutics Stock Up 1.6%

SABS stock opened at $3.70 on Thursday. The company has a market cap of $176.16 million, a price-to-earnings ratio of -1.20 and a beta of 0.58. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $6.60. The business has a 50 day moving average price of $3.00 and a two-hundred day moving average price of $2.42. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. Analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC bought a new position in SAB Biotherapeutics during the third quarter worth $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $32,000. Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $40,000. HB Wealth Management LLC bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $618,000. Finally, Woodline Partners LP acquired a new position in SAB Biotherapeutics in the 3rd quarter valued at about $5,730,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.